Analysis of the chondrogenic potential and secretome of mesenchymal stem cells derived from human umbilical cord stroma.
Mesenchymal stem cells (MSCs) from umbilical cord stroma were isolated by plastic adherence and characterized by flow cytometry, looking for cells positive for OCT3/4 and SSEA-4 as well as the classic MSC markers CD44, CD73, CD90, Ki67, CD105, and CD106 and negative for CD34 and CD45. Quantitative reverse transcriptase-polymerase chain reaction analysis of the genes ALP, MEF2C, MyoD, LPL, FAB4, and AMP, characteristic for the differentiated lineages, were used to evaluate early and late differentiation of 3 germ lines. Direct chondrogenic differentiation was achieved through spheroid formation by MSCs in a chondrogenic medium and the presence of chondrogenic markers at 4, 7, 14, 28, and 46 days of culture was tested. Immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analyses were utilized to assess the expression of collagen type I, collagen type II, and collagen type X throughout the time studied. We found expression of all the markers as early as 4 days of chondrogenic differentiation culture, with their expression increasing with time, except for collagen type I, which decreased in expression in the formed spheroids after 4 days of differentiation. The signaling role of Wnt during chondrogenic differentiation was studied by western blot. We observed that β-catenin expression decreased during the chondrogenic process. Further, a secretome study to validate our model of differentiation in vitro was performed on spheroids formed during the chondrogenesis process. Our results indicate the multipotential capacity of this source of human cells; their chondrogenic capacity could be useful for future cell therapy in articular diseases.
Arufe
Maria C
MC
Department of Medicine, Area of Anatomy and Human Embryology, Faculty of Health Science, University of A Coruña, A Coruña, Spain.
De la Fuente
Alexandre
A
Mateos
Jesus
J
Fuentes
Isaac
I
De Toro
Francisco J
FJ
Blanco
Francisco J
FJ
D050156:Adipogenesis; D000328:Adult; D000704:Analysis of Variance; D015153:Blotting, Western; D018929:Cell Culture Techniques; D002454:Cell Differentiation; D002478:Cells, Cultured; D020219:Chondrogenesis; D003094:Collagen / Q000378:metabolism; D003239:Connective Tissue Cells / Q000166:cytology* / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel / Q000379:methods; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D032342:Muscle Cells / Q000166:cytology / Q000378:metabolism; D024510:Muscle Development; D010012:Osteogenesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D055746:Stage-Specific Embryonic Antigens / Q000378:metabolism; D014470:Umbilical Cord / Q000166:cytology*; D051176:beta Catenin / Q000378:metabolism
C495270:CTNNB1 protein, human; D055746:Stage-Specific Embryonic Antigens; D051176:beta Catenin; C066584:stage-specific embryonic antigen-4; D003094:Collagen